Tehrani Fateh Sepand, Behgozin Abbas, Yekani Farshid, Geranpayeh Lobat, Olfatbakhsh Asieh, Moghaddam Shiva, Sarami Forroshani Ramin, Salehi-Najafabadi Amir, Shekari Faezeh
School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
R&D Division, Tashkhis Fan Firoozeh (Firoozeh DiaTech), Tehran, Iran.
Cell J. 2023 Jan 1;25(1):73-75. doi: 10.22074/cellj.2022.562589.1134.
Considering HER2 as one of the well-known biomarkers in the cancer field, and published articles regarding serum levels of HER2, in this paper we tried to highlight the issue that most studies don't stratify the HER-2 concentration of individuals in terms of gender. In this brief survey, healthy individuals with no prior non-communicable diseases were categorized as males (n=34) and females (n=43), and all samples were evaluated for plasma HER-2 levels at once. Surprisingly, the plasma level of HER-2 of healthy male individuals (mean= 2.28 ± 0.21 ng/mL) was significantly (P<0.0001) higher than the plasma level of HER-2 of healthy females (mean: 0.06 ± 0.09 ng/mL), with no overlap. Therefore, we suggest that more studies are required to re-check the cutoff values for HER-2 plasma levels based on gender since the clinical implications of a unique HER-2 cutoff for both genders may be seriously concerning.
鉴于HER2是癌症领域著名的生物标志物之一，且有关于血清HER2水平的已发表文章，在本文中我们试图强调一个问题，即大多数研究并未根据性别对个体的HER-2浓度进行分层。在这项简短的调查中，没有既往非传染性疾病的健康个体被分为男性（n = 34）和女性（n = 43），所有样本一次性评估血浆HER-2水平。令人惊讶的是，健康男性个体的血浆HER-2水平（平均值 = 2.28 ± 0.21 ng/mL）显著高于（P<0.0001）健康女性的血浆HER-2水平（平均值：0.06 ± 0.09 ng/mL），且无重叠。因此，我们建议需要更多研究根据性别重新检查HER-2血浆水平的临界值，因为单一HER-2临界值对两性的临床意义可能令人严重担忧。
